The Experts below are selected from a list of 360 Experts worldwide ranked by ideXlab platform

E. John Gallagher - One of the best experts on this subject based on the ideXlab platform.

  • A Randomized, Double-Blind, Placebo-Controlled Trial of Naproxen With or Without Orphenadrine or Methocarbamol for Acute Low Back Pain
    2017
    Co-Authors: Benjamin W. Friedman, Clemencia Solorzano, David Cisewski, Eddie Irizarry, Adam Nassery, Scott Pearlman, Michelle Davitt, Deborah White, E. John Gallagher
    Abstract:

    Study objective: In US emergency departments (EDs), patients with low back pain are often treated with nonsteroidal anti-inflammatory drugs and muscle relaxants. We compare functional outcomes among patients randomized to a 1-week course of naproxen+placebo versus naproxen+orphenadrine or naproxen+Methocarbamol. Methods: This was a randomized, double-blind, comparative effectiveness trial conducted in 2 urban EDs. Patients presenting with acute, nontraumatic, nonradicular low back pain were enrolled. The primary outcome was improvement on the Roland-Morris Disability Questionnaire (RMDQ) between ED discharge and 1 week later. All patients were given 14 tablets of naproxen 500 mg, to be used twice a day, as needed for low back pain. Additionally, patients were randomized to receive a 1-week supply of orphenadrine 100 mg, to be used twice a day as needed, Methocarbamol 750 mg, to be used as 1 or 2 tablets 3 times per day as needed, or placebo. All patients received a standardized 10-minute low back pain educational session before discharge. Results: Two hundred forty patients were randomized. Baseline demographic characteristics were comparable. The mean RMDQ score of patients randomized to naproxen+placebo improved by 10.9 points (95% confidence interval [CI] 8.9 to 12.9). The mean RMDQ score of patients randomized to naproxen+orphenadrine improved by 9.4 points (95% CI 7.4 to 11.5). The mean RMDQ score of patients randomized to naproxen+Methocarbamol improved by 8.1 points (95% CI 6.1 to 10.1). None of the between-group differences surpassed our threshold for clinical significance. Adverse events were reported by 17% (95% CI 10% to 28%) of placebo patients, 9% (95% CI 4% to 19%) of orphenadrine patients, and 19% (95% CI 11% to 29%) of Methocarbamol patients. Conclusion: Among ED patients with acute, nontraumatic, nonradicular low back pain, combining naproxen with either orphenadrine or Methocarbamol did not improve functional outcomes compared with naproxen+placebo.

Hanaa S Eldesoky - One of the best experts on this subject based on the ideXlab platform.

  • electrochemical determination of Methocarbamol on a montmorillonite ca modified carbon paste electrode in formulation and human blood
    2010
    Co-Authors: Enass M Ghoneim, Hanaa S Eldesoky
    Abstract:

    Utilizing the fascinating strong adsorptive ability, high chemical and mechanical stability properties of montmorillonite-calcium (MMT-Ca) clay, a MMT-Ca modified carbon paste electrode was developed for the sensitive determination of Methocarbamol. Methocarbamol has been oxidized in buffered solutions at the developed MMT-Ca-modified CPE in a single 2-electron irreversible anodic peak. A simple and sensitive square-wave adsorptive anodic stripping voltammetric method was optimized for determination of Methocarbamol in bulk form, pharmaceutical formulation and in spiked human serum using the developed modified CPE. This was carried out without the necessity for samples pretreatment and/or time-consuming liquid-liquid or solid-phase extraction steps prior to the analysis. The developed electrode exhibited an excellent sensitivity and selectivity towards Methocarbamol even in the presence of 10(2)-10(4)-fold of its active ingredient "ibuprofen," common excipients, common metal ions or co-administrated drugs. Limits of detection of 3 x 10 (-9) and 1.2 x 10(-8) M and limits of quantitation of 1 x 10(-8), and 4 x 10(-8) M Methocarbamol were achieved in the bulk form and in spiked human serum, respectively. Moreover, the developed method was successfully applied for determination of Methocarbamol in human plasma of subjects following administration of an oral dose of Ibuflex tablets.

Heinrich Brinkmeier - One of the best experts on this subject based on the ideXlab platform.

  • Methocarbamol blocks muscular nav1 4 channels and decreases isometric force of mouse muscles
    2021
    Co-Authors: Yaxin Zhang, Philipp Otto, Lu Qin, Nane Eiber, Said Hashemolhosseini, Stephan Kroger, Heinrich Brinkmeier
    Abstract:

    BACKGROUND The muscle relaxant Methocarbamol is widely used for the treatment of muscle spasms and pain syndromes. To elucidate molecular mechanisms of its action, we studied its influence on neuromuscular transmission, on isometric muscle force, and on voltage-gated Na+ channels. METHODS Neuromuscular transmission was investigated in murine diaphragm-phrenic nerve preparations and muscle force studied on mouse soleus muscles. Nav 1.4 channels and Nav 1.7 channels were functionally expressed in eukaryotic cell lines. RESULTS Methocarbamol, at 2 mM, decreased the decay of endplate currents, slowed the decay of endplate potentials and reduced tetanic force of soleus muscles. The drug reversibly inhibited current flow through muscular Nav 1.4 channels, while neuronal Nav 1.7 channels were unaffected. CONCLUSIONS The study provides evidence for peripheral actions of Methocarbamol on skeletal muscle. Muscular Na+ channels are a molecular target of Methocarbamol. Since Nav 1.7 currents were unaffected, Methocarbamol is unlikely to exert its analgesic effect by directly blocking Nav 1.7 channels.

  • Methocarbamol blocks muscular na v 1 4 channels and decreases isometric force of mouse muscles
    2021
    Co-Authors: Yaxin Zhang, Philipp Otto, Lu Qin, Nane Eiber, Said Hashemolhosseini, Stephan Kroger, Heinrich Brinkmeier
    Abstract:

    Background The muscle relaxant Methocarbamol is widely used for the treatment of muscle spasms and pain syndromes. To elucidate molecular mechanisms of its action, we studied its influence on neuromuscular transmission, on isometric muscle force, and on voltage-gated Na+ channels. Methods Neuromuscular transmission was investigated in murine diaphragm-phrenic nerve preparations and muscle force studied on mouse soleus muscles. Nav 1.4 channels and Nav 1.7 channels were functionally expressed in eukaryotic cell lines. Results Methocarbamol, at 2 mM, decreased the decay of endplate currents, slowed the decay of endplate potentials and reduced tetanic force of soleus muscles. The drug reversibly inhibited current flow through muscular Nav 1.4 channels, while neuronal Nav 1.7 channels were unaffected. Conclusions The study provides evidence for peripheral actions of Methocarbamol on skeletal muscle. Muscular Na+ channels are a molecular target of Methocarbamol. Since Nav 1.7 currents were unaffected, Methocarbamol is unlikely to exert its analgesic effect by directly blocking Nav 1.7 channels.

Eglal A Abdelaleem - One of the best experts on this subject based on the ideXlab platform.

Ehab F Elkady - One of the best experts on this subject based on the ideXlab platform.